Introduction: 1
Antigen recognition by cytotoxic T cells and subsequent tumour cell destruction is the 2 key component underlying cancer immunotherapy strategies. Its importance has been 3 widely demonstrated, and loss-of-function of elements in the antigen processing and 4 presentation pathways has been shown to confer therapeutic resistance [1] . Correlative 5 findings point to neo-antigens arising from tumour mutations as an important source 6 of immunogenic antigens in the context of melanoma and other cancers [2] . 7
Nonetheless, tumours with low mutational burdens can respond to checkpoint 8 inhibitor therapy, and the presence of a high tumour-mutational load does not 9 necessarily correspond to the efficacy of treatment [3] . HLA-presented peptides (p-10 HLA-I) arising from the mutant proteins are mostly heterogeneously expressed and 11 additionally determined by the patient-specific HLA-subtypes, making predictions 12 about their presentation and immunogenicity unreliable. While a number of recent 13 studies have reported the utility of mass spectrometry combined with exome 14 sequencing in identifying HLA-presented peptides derived from mutated proteins [4-15 6] , the analysis of the contribution of mutational neo-antigens to the overall tumour 16 immunogenicity remains complicated and unresolved. 17 Against this background, the composition of the immunopeptidome, or the repertoire 18 of HLA-bound peptides presented on the surface of the cell and their contribution to 19 tumour immune recognition, becomes significant. The immunopeptidome is largely 20 shaped by antigen processing through the proteasome complex for subsequent 21 presentation of short peptide epitopes on MHC molecules [7] . Several forms of the 22 proteasome complex exist, each with differing enzymatic activities [8] . In melanoma 23 cells, the constitutive proteasome (cP) is expressed under steady state conditions. The 24 expression of an immunoproteasome (IP), the subtype expressed by dendritic cells 25 and other cells of the immune system, may be induced in tumour cells in a cytokine-1 dependant manner [9] , leading ultimately to changes in the peptides presented to the 2 immune system [10, 11] . We have previously demonstrated induction of the IP in a 3 range of human melanoma cell lines in the presence of the inflammatory cytokine 4 IFN in vitro, and in melanoma patient inflamed tumours (characterised by presence 5 of tumour infiltrating lymphocytes (TILs)) ex vivo [12] . Dependant on the proteasome 6 subtype expressed by the cell, we have subsequently shown that a single melanoma 7 antigen (NY-ESO-1) has the potential for cleavage into multiple differing epitopes. 8
These differences in antigen processing led to concomitant change in the ability of 9 antigen specific T cells to target the tumour cell. Thus, the potential for a tumour cell 10 to 'look' substantially different to CD8 + T cells, depending on inflammation at the 11 tumour site, arises. Moreover, recent studies by ourselves and others [13, 14] have 12 shown that a significant proportion of p-HLA-I are not genomically templated and 13 result from post-translational proteasome splicing (ligation of non-contiguous small 14 polypeptide segments from the same or different proteins). To date, these peptides 15 have been missed in most neoantigen discovery studies due to the lack of appropriate 16 bioinformatics tools [15, 16] . In this study we have used high resolution mass 17 spectrometry approaches (both data-dependent and data-independent acquisition mass 18 spectrometry) combined with a novel bioinformatics workflow to not only 19 demonstrate significant changes in the melanoma immunopeptidome based on 20 presence or absence of the cytokine IFNγ, but also to identify and quantify cis-spliced 21 p-HLA-I presented by melanoma cells under both conditions. Those peptides derived 22 from melanoma-associated or over-expressed proteins were tested for ex vivo 23 immunogenicity in melanoma patients and healthy donors. Both linear and spliced 24 peptides were found to be immunogenic in both donor groups. Notably, T lymphocyte 25 responses to pools of IFNγ upregulated peptides were not seen in healthy donors. We 1 also demonstrate for the first time that cis-spliced peptides are widely presented by 2 melanoma cells and immunogenic in multiple donors. These findings have significant 3 implications for cancer immunotherapy as well as for fundamental questions such as 4 induction of immune-tolerance, T cell repertoires and pathogen recognition. HLA class I peptides were eluted from LM-MEL-44 cells (prior to or after treatment 5 with IFNγ) as described previously [24] [25] [26] . In brief, 3 x 10 9 cells were lysed in 0.5% 6 IGEPAL, 50 mM Tris-HCl pH 8.0, 150 mM NaCl supplemented with protease 7 inhibitors (CompleteProtease Inhibitor Cocktail Tablet; Roche Molecular 8 Biochemicals) for 45 min at 4 °C. Lysates were cleared by ultracentrifugation at 9 40,000 g and HLA class I complexes were immunoaffinity purified using W6/32 (pan 10 anti-HLA-A, B, C) and DT9 (anti HLA-C) monoclonal antibodies. 11
12
Fractionation of HLA-bound peptides by reversed-phase high-performance liquid 13 chromatography (RP-HPLC) 14
The HLA-peptide eluates were loaded onto a 4.6 mm internal diameter x 50 mm 15 monolithic C18 RP-HPLC column (Chromolith Speed Rod; Merck) at a flow rate of 1 16 ml/min using an EttanLC HPLC system (GE Healthcare) with buffer A (0.1% 17 trifluoroacetic acid (TFA)) and buffer B (80% ACN / 0.1% TFA) as mobile phases. 18
The bound peptides were separated from the class I heavy chains and ß2m molecules 19 using increasing concentration of buffer B. Peptide-containing fractions (500 µl) were 20 collected, vacuum concentrated to ~5 µl and reconstituted to 15 µl with 0.1 % formic 21 acid (FA). The identical instrument setup as described above (Dionex UltiMate 3000 LC system 17 coupled to a QExactive Plus mass spectrometer) was used to quantify HLA-bound 18 peptides using data-independent acquisition (DIA). In each cycle, 28 sequential DIA 19 windows with an isolation width of 25 m/z between 300 -1000 Da were acquired 20 (resolution: 17.500; AGC target: 2e5; maximum IT: auto; NCE: 27) following a full 21 ms1 scan (resolution: 70.000; AGC target: 3e6; maximum IT: 55 ms; scan range: 300-22 1000 m/z). A 90 min gradient of increasing concentrations of 80% ACN / 0.1% FA 23 was used to separate the peptides for the DIA acquisition. 24 25 DDA data analysis 1 Linear and cis-spliced peptide sequences were identified as described previously [14] . were purified by density centrifugation over Ficoll Hi-Paque. Cells were cultured in 24 TCRPMI consisting of RPMI 1640, 2mM Glutamax, 100 IU/ml Penicillin, 100 µg/ml 25 Streptomycin, 20 mM HEPES, 1% nonessential amino acids, 1 mM sodium pyruvate, 1 55 µM β -mercaptoethanol, and 10% human AB serum (Australian Red Cross, VIC, 2 Australia). Peptides were combined into pools of 5-9 peptides as outlined in 3 Supplementary Table 6 . 10 6 PBMC/ml were incubated with 10µM each peptide in 4 pools for 10 -12 days at 37 °C. IL-2 (100 IU/ml) was added and replaced every 3 5 days. 6 7
Intracellular cytokine staining (ICS) of antigen-activated T-lymphocytes 8
To assess antigen responses, T-lymphocytes were restimulated (following 10 -12 9 days incubation as outlined above) with peptide pools for 4-8 h in TCRPMI in 10 presence of 10 µg/ml brefeldin A (BFA, Golgi plug). Cells were washed with PBS 11 (Invitrogen) labeled with live/dead fixable violet stain (Invitrogen), then incubated 12 with antibodies against CD3 and CD8 (BD biosciences) for 15 min at 4°C. Samples 13 were washed and fixed for 20 min at 4°C. Cells were permeabilised and stained with 14 anti-TNFα (eBiosciences) for 25 min at 4°C. The gating strategy was: SSC/FSC; 15
Singlets; SSC/LD -; CD3 + /CD8 + ; CD8 + /TNFα + . Data were acquired on a FACSCanto 16 (BD biosciences, VIC Australia) and analyzed with FlowJo software (Version 10, 17
FlowJo, Ashland OR, USA). To account for the large variation in DMSO background 18 CD8 + T cell activity across multiple donors, signals were normalized by subtracting 19 the background from DMSO control treated samples in each case. 20
21

HLA-A2 stabilisation assays 22
The binding activity of the peptides was assayed by measuring peptide-induced 23 stabilization of HLA-A2 on TAP-deficient T2 cells by flow cytometry. T2 cells were 24 cultured in RF-10 (RPMI with 10% serum, 5% Glutamine, 5% Pen/Strep) in T25 25 flasks for 2 -3 days before the assay. T2 cells (2x 10 5 cells/well) were cultured for 16 1 h at 37 o C in 5% CO 2 in 200 µL RF-10 in 96-well U-bottomed plates in presence or 2 absence of 10 µg/ml of synthetic peptides. Peptides from Melan-A (modified aa26-35 3
ELA……and aa 60-72) served as a positive or negative controls respectively. All 4 peptides were tested in triplicate. 5
After 16 h stimulation the cells were washed and stained with anti-HLA A2 6 monoclonal antibody BB7.2 (Biolegend) for 30 min. at 4 o C. Cells were subsequently 7 stained with Fixable Viability Kit (Zombie NIR™, Biolegend) for 15 min. at 4 o C 8 before flow cytometry on a FacsCanto (BD). Data was analysed using FlowJo 9 software (Version 10, FlowJo, Ashland OR, USA). 10 11
Results: 1
The melanoma immunopeptidome contains a large proportion of cis-spliced peptides. 2
To establish a comprehensive repository of HLA class I peptide ligands presented by 3 melanoma cells utilizing either the canonical proteasome (cP) or the 4 immunoproteasome (IP), we cultured the patient-derived melanoma cell line in the absence or presence of IFN for 3 days to allow for turnover of 6 the cell-surface presented epitopes [29] , and then subjected to the workflow outlined in 7 Figure 1a . Briefly, HLA class I molecules were affinity purified with the HLA-C (DT- 8 9) and pan-HLA-ABC antibodies (W6/32) and HLA-bound peptides were pre-9 fractionated by HPLC prior to analysis by data-dependent acquisition mass 10 spectrometry (DDA-MS). Data was analysed by Peaks 8.5 software and spliced 11 peptides further characterised using the HybridFinder algorithm [14] . 12
We identified a total of 30,120 peptides (derived from 12,025 source proteins) 13 presented across all HLA class I allotypes expressed by the LM-MEL-44 cells at a 14 false discovery rate (FDR) of 1% ( Supplementary Table 1 ). Approximately 6% of 15 these peptides (1,821 peptides) were assigned as cis-spliced in origin (Fig 1b, proportion of peptides of cis-spliced origin is in agreement with our previous 21 study [14] and others [30, 31] . As expected for HLA class I epitopes, the majority of 22 peptides (27,321 peptides; ˜90%) were between 8-12 amino acids in length with no 23 apparent difference between linear and cis-spliced sequences ( Supplementary Figure  24 1b). Using the NetMHCpan binding algorithm [32] , 91.2% of these 8-12mers were 25 predicted to bind to at least one of the HLA class I alleles expressed on the surface of 1 the LM-MEL-44 cells (A*02:01,B*60/*44:02,C*03:04/*05:01) [33] suggesting that 2 the majority of the identified peptide sequences can be considered genuine HLA class 3 I ligands (Supplementary Table 2 ). The percentage of predicted binders was lower for 4 cis-spliced peptides compared to linear peptides (68.5% vs. 92.9%), which can be 5 attributed to the fact that NetMHCpan and other binding algorithms have been 6 developed and based on consensus-binding motifs of linear epitopes, which can differ 7 slightly from consensus-binding motifs of cis-spliced peptides [13, 14] . Indeed, similar 8 marginal differences between the consensus-binding motifs of linear and cis-spliced 9 epitopes are also evident in this dataset, which are more pronounced at the N-terminal 10 anchor positions P2 / P3 compared to the C-terminal PΩ position (Figure 1c ). 11
Taken together, we identified more than 30,000 predominantly novel HLA class I 12 ligands presented on the surface of the LM-MEL-44 melanoma cells including nearly 13 2,000 cis-spliced peptides, which have not been described before. Of note, none of the 14 mutational neoantigens predicted based on exome sequencing data of LM-MEL-15 44 [34] were identified in our dataset ( Supplementary table 3 pool. Considering the well-described clinical relevance of so called "hot" versus 20 "cold" tumour microenvironments and previous work demonstrating the influence of 21 cytokine exposure on antigen-presentation pathways[10], we wanted to examine on a 22 global scale the impact of IFNγ exposure on the immunopeptidome. An initial 23 qualitative analysis revealed that only 49.3% of the 30,120 peptides were identified 24 under both conditions demonstrating that the addition of IFN significantly changes 25 the composition of the immunopeptidome (Figure 2a ). To measure these differences 1 quantitatively, we combined all IFN -treated or non-treated fractions and analysed 2 these samples by data-independent acquisition mass spectrometry (DIA-MS; Figure  3 1a) using a spectral library, which has been created based on our DDA data in the 4 presence of iRT peptides ([27] ; Supplementary Figure 2 ). After applying stringent 5 filter criteria, we were able to quantify a total of 9,799 peptides (Supplementary Table  6 4). 3,553 of these peptides (˜36%) were only quantified in one of the two conditions 7 with a q-value of less than 1% and can be considered as condition-specific, which is 8 in good agreement with our initial comparative analysis. 9
The remaining 6,246 peptides (˜64%) were quantified in both conditions with 10 corresponding q-values of less than 1% suggesting that these peptides are presented 11 by melanoma cells both in the presence and absence of IFN . To determine their 12 degree of variation, we calculated their log2 fold changes (+IFN /-IFN ) and 13 plotted these values as violin plots separately for linear and cis-spliced peptides 14 ( Figure 2b) . A considerable proportion (2,183 peptides, ˜35%) were observed to 15 change in abundance by at least by a factor of 2, confirming that the addition of IFN 16 substantially changes HLA class I presentation, while not affecting the proportion of 17 presented cis-spliced epitopes on LM-MEL-44 melanoma cells. 18
This DIA-MS dataset contains 439 peptides, which have been quantified based on 19 their doubly as well as triply charged precursor ions in both conditions. The resulting 20 fold changes are nearly identical with a Pearson correlation coefficient of 0.899 (p-21 value <0.001) and a near perfect linear regression curve ( Supplementary Figure 3) , 22 which highlights the precision of the quantitation using DIA-MS data. 23 24 Identification of novel cancer specific peptides in the melanoma immunopeptidome. 1 Next we screened our results for peptides derived from proteins previously described 2 as melanoma-associated antigens (MAA) [35, 36] as well as for tumour antigens with 3 demonstrated immunogenicity [37] [38] [39] . We identified a total of 712 peptides in our 4 dataset (674 linear, 38 spliced peptides) derived from 96 different MAAs (Figure 3a , 5 Supplementary Table 5 ). Approximately 10% of the linear MAA-derived peptides 6 identified in our study have previously been described as CD8 + T cell epitopes, thus a 7 high proportion of the linear peptides and all of those generated by splicing, constitute 8 novel peptides (Figure 3b ). Of the previously reported epitopes, the majority were 9 present in both the presence and absence of IFN , whereas >28% of novel peptides 10 were exclusive to IFN treated samples, demonstrating the importance of carefully 11 considering experimental conditions for epitope identification (Figure 3c) . 12 13 CD8 + T lymphocytes frequently recognised novel linear melanoma-specific epitopes. 14 HLA-A2 is one of the most prevalent HLA-types worldwide, and efforts to identify 15 common HLA-peptides for a large number of patients often focus on this serotype. 16
Therefore, we addressed functional immunogenicity of a selection of predicted HLA-17 A2 binding, novel linear melanoma-specific epitopes by using them to stimulate CD8 + 18 T lymphocytes in PBMC derived from healthy donors or melanoma patients 19
( Supplementary table 6 ). To confirm their A2 specificity, we have included HLA-A2 20 negative melanoma patients and healthy donors as controls wherever feasible, here 21 represented by melanoma patient 6. Alongside these assays, we also assessed 22 differences in functional immunogenicity of IP or cP processed epitopes by pooling 23 these peptides into groups of those which were up-or down-regulated following 24 IFN treatment (Figure 4 ). Of note, the LM-MEL-44 cell line was derived from 25 melanoma patient 2. We found that CD8 + T lymphocyte responses to the tested 1 peptides were more frequently seen in melanoma patients (Figure 4a (individual) and 2 4b (pooled donors)). Novel peptides derived from 15 of the melanoma antigens 3 identified in our screen stimulated specific CD8 + T lymphocyte responses (over 2% 4 TNFα + cells) in three or more donors, demonstrating novel, functional, melanoma T 5 cell epitopes (highlighted in Supplementary Table 6 , Representative examples, Figure  6 4c). The strongest responses were induced by the peptides derived from SART1 7 (U4/U6.U5 tri-snRNP-associated protein 1) and PGK1 (Phosphoglycerate kinase 1), 8 both of which stimulated responses in 2-7% of T lymphocytes from 4 melanoma 9 patients. When the same selection of peptides were pooled in groups of those up/down 10 regulated, or unchanged following IFN treatment no appreciable difference in 11 functional immunogenicity in melanoma patients was observed between groups. 12
Interestingly however, T lymphocyte responses to pools of IFNγ upregulated peptides 13 were not seen in healthy donors. One pool in each group was made on the basis of 14 higher in silico-predicted immunogenicity (www.iedb.org [40] , Figure 4a ,b, asterisks). 15
However, these groups did not display enhanced ability to activate CD8 + T 16 lymphocytes in either melanoma patients or healthy donors. 17 18
Melanoma patients expressing immunoproteasome genes have a survival advantage. 19
Tumour recognition in vivo relies on the processing and generation of cognate 20 peptides within the tumour cells. As antigen presenting cells (APCs) use the 21 immunoproteasome for protein processing and subsequent HLA-loading, tumours that 22 express the IP as opposed to the constitutive form should display a similar peptide 23
repertoire as APCs, which should avoid T-cell-p-HLA mismatch and therefore lead to 24 a greater likelihood of encountering matched T cells. Using OncoLnc[41], we mined 25 gene-expression data generated by the TCGA Research Network 1 (http://cancergenome.nih.gov/) for correlation of both IP and cP-specific genes with 2 survival in melanoma patients. We found that expression of all three IP-specific 3 subunits was highly significantly associated with survival in melanoma patients. 4
Conversely, cP-specific subunits were associated with decreased melanoma patient 5 survival ( Figure 5 ). 6
Since IP subunits are also expressed by immune cells, including TILs, we removed 7 the top quartile of samples with the highest CD3 expression. In these tumours IP 8 expression to a large extent is likely generated by immune infiltrates themselves. 9
Following removal of these samples, we found that a significant survival benefit, 10 associated with 2/3 IP subunits, was maintained ( Supplementary Figure 4) . 11
Furthermore, presence of the 3 cP subunits was associated with a trend towards 12 decreased survival. This indicates that patients whose tumours express an IP have 13 survival benefit which is specifically associated with this proteasome type. As IP 14 expression in tumours is driven by cytokine exposure it remains unclear if this is 15 merely a footprint of a successful immune recognition or if it is part of the pre-16 conditions to allow for it. 17
18
Spliced peptides are immunogenic across patients and represent novel targets for 19
immunotherapy 20
The potential implications of the presence of spliced peptides for all facets of 21 immunity have sparked intense discussions in the last 2 years [14, [42] [43] [44] . In cancer, 22 their presence would dramatically widen the repertoire of potentially targetable 23 epitopes and may allow for many more tumour-specific antigens (including 24 mutational derived neoantigens) being presented in various HLA-contexts. So far only 25 6 immunogenic cis-spliced peptides derived from 4 different proteins [42] have been 1 described and most of them have been discovered by T cell assays rather than by mass 2 spectrometry [45] [46] [47] [48] [49] [50] . To test some of the identified spliced peptides for their ability to 3 activate CD8 + T cells in-vitro we synthesized 26 cis-spliced peptides based on (i) 4 their de-novo sequencing confidence score, (ii) their NetMHC4 binding prediction 5 score for 3 HLA alleles expressed on LM-MEL-44 cells (HLA-A*02:01, HLA-6 B*44:02 or HLA-C*05:01) and (iii) the quality of their peptide spectrum matches 7 (PSMs). When employed as pools of 8-9 individual peptides, all 3 pools evoked 8 immune-responses as measured by intracellular TNFα production in CD8 + T cells 9 (Figure 6a ) in multiple HLA-A2 positive melanoma patients. These responses were 10 more prominent in patients compared to healthy HLA-A2 + donors (Figure 6b ). 11
Given the differences in the potential to stimulate HLA-A2 positive vs. negative 12 patient and healthy donor samples, most of the immunogenic peptides in our assays 13 seem to be HLA-A2 associated. To identify specific immunogenic peptides, PBMCs 14 were stimulated with the peptide pools (Figure 7a ) for 10-12 days followed by single 15 peptide re-stimulation. Six out of 26 peptides induced a TNF-α response above 16 background (Figure 7b ) in at least one melanoma patient. Of note, the peptide 17 demonstrating the highest immunogenicity based on these assays is a spliced peptide 18 derived from a cancer-testis antigen, MAGE-C2 and showed CD8 + T cell activation 19 across 3 patients. These data show that these spliced peptides can serve as bona fide 20 anti-cancer targets and provide a large number of additional targets that have been 21 previously unknown. Of note, all immunogenic peptides that tested positive for 22 immunogenicity in our assays were subjected to T2 peptide binding assays to confirm 23 their HLA A2 specificity. As shown in Figure 7c , these peptides all stabilize HLA-24 A2, albeit weaker than the well described modified ELAGIGILTV HLA-A2 peptide 1 (aa26-35) from the melanoma antigen Melan-A[51]. 2 3
Discussion: 4
In this study we have established a detailed and in-depth immunopeptidome presented 5 on the LM-MEL-44 cell line, which is a patient-derived melanoma cell line derived 6 from a lymph node metastasis. Our qualitative assessment of the immunopeptidome 7 yielded over 30,000 high confidence peptide identifications that encompassed two 8 culture conditions (+/-IFNγ). Surprisingly only 50% of these peptides were identified 9 in both conditions. To more accurately assess the overlap and plasticity of the LM-10 MEL-44 immunopeptidome we used data-independent acquisition mass spectrometry 11 (DIA-MS) to quantify the IFNγ induced changes in the melanoma immunopeptidome. 12
Although this state-of-the-art, mass spectrometric technique has been developed 13 several years ago [52, 53] , only a handful of studies have exploited DIA-MS to 14 quantify HLA peptide ligands so far [38, [54] [55] [56] [57] [58] . The well-described effect of IFN in 15 mediating changes to the composition of the antigen processing machinery, coupled 16 with reports of differences in antigen processing between the cP and the IP over 17 several years, led us to expect a degree of difference between the two 18 immunopeptidomes. Nevertheless, our observation that ~35% of the HLA class I 19 epitopes were exclusive to either IFNγ treated or untreated conditions, and that an 20 additional 35% were observed to change more than 2-fold in presence of IFN , 21 reflect the profound impact of this cytokine on the composition of the 22 immunopeptidome. Our observations are also consistent with recent studies in ovarian 23 and lung cancer [10, 11] . For example, in ovarian cancer, a 9% difference in peptides 24 presented between IFNγ treated/untreated conditions was observed following 24 h of 1 IFNγ treatment (as opposed to 72 h in our study) . 2 In our study, MAA-derived peptides were found in roughly equal proportions in IFNγ 3 treated (28.8%), or untreated (20%) settings. Interestingly however, of the MAA 4 epitopes that have been previously described in other studies, only 2.8% were present 5 in IFNγ treated (IP) conditions (Figure 5c ). This observation suggests that many IP 6 processed epitopes may be as yet undescribed, since traditional approaches to identify 7 tumour associated antigens have largely been undertaken using cells lines under 8 steady state conditions (i.e. which express cP). Furthermore, of the previously 9 described cancer cis-spliced peptides, 3 have been shown to be processed exclusively 10 by the cP, and 2 by both the cP and the IP (and 1 undetermined) [42] . 11
It is evident from our study that the steady state immunopeptidome may vary 12 dramatically from the in vivo tumour scenario depending on the tumour 13 microenvironment at any given time. Though our functional studies did not reveal a 14 difference in the immunogenicity of peptides derived from either IFNγ treated or 15 untreated conditions, in the in vivo setting a T cell response to IFNγ related epitopes is 16 likely to be aided by correlative IFNγ influences, such as upregulation of surface 17 HLA [59] . Taken together, it is tempting to speculate that antigen processed via the 18 IP may represent an untapped resource of "IFNγ-associated neo-epitopes". 19
The potential for tumour escape from CD8 + T lymphocyte killing due to whole scale 20 change to the immunopeptidome upon initiation of an anti-tumour responses, and 21 corresponding induction of IFNγ is clear. These data become particularly significant 22 in the context of recent studies demonstrating that tumours with an IFN -inflamed, or 23 'hot' microenvironment are associated with better prognosis, and are more likely to be 24 amenable to treatment with immune checkpoint inhibitors [60] . It seems conceivable 25 that in vivo the difference between immunopeptidomes is indeed of immunological 1 relevance to disease progression and overall patient prognosis. 2
The identification of spliced peptides as tumour antigens in cancer was first described 3 in 2004 in both the FGF5 protein in renal cancer [45] and the gp100 protein in 4 melanoma [46] , and since then only a further 4 cis-spliced peptides have been 5 described in cancer [42] . To date their identification has been hampered by lack of 6 feasible identification methods. In this study, we have used high-resolution mass 7 spectrometry to identify more than 30,000 endogenous HLA class I peptide ligands. 8 Approximately 2,000 (6%) of these peptides represent cis-spliced peptides 9
demonstrating that cis-spliced peptides are commonly generated in cancer cells, which 10 broadens the repertoire of potential targets in cancer immunotherapy. Consistent with 11 our observations a recent study by Liepe et al[13] identified 750 and 486 cis-spliced 12 peptides in colon and breast cancer cell lines respectively -however their 13 immunogenicity was not described. Of note, 38 of our 2,000 cis-spliced peptides (and 14 712 of all identified peptides) were derived from melanoma-associated antigens, and 15 with the exception of a few linear epitopes, none of these epitopes have been 16 described before. Interestingly, of those that had been described, most were identified 17 by mass spectrometry based immunopeptidome screening studies [38, 39] . Although 18 others have identified HLA-binding cis-spliced epitopes by bioinformatic approaches 19 [11, 61] , few have addressed the functional immunogenicity of the identified epitopes 20 -i.e. can a T lymphocyte recognise and respond to it? Importantly, we demonstrated 21 functional immunogenicity of 6 (23%) of the cis-spliced epitopes, which represents a 22 significant advance in the field since it doubles the number of known immunogenic 23 cancer cis-spliced peptides and validates a platform to identify these going forward. 24 (Biognosys). To identify quantitative differences in the immunopeptidome prior to or 10 after treatment with IFNγ, the remaining DT9 and W632 eluates were pooled and 11 analyzed by data-independent acquisition (DIA) mass spectrometry on a QExactive 12 Plus mass spectrometer (Thermo Scientific). Data were imported and analyzed with 13 Spectronaut 11 Pulsar (Biognosys). 14 (B) During proteolysis, the proteasome generates short linear peptides through 15 hydrolysis of the peptide bonds. These peptides directly match the proteome. 16
Alternatively, transpeptidation reactions can generate peptides which do not have a 17 template in the genome. Such spliced peptides could originate from one (cis-spliced) 18 or two (trans-spliced) distinct proteins. 19 (C) Consensus-binding motifs were generated for the identified linear and cis-spliced 20 nonameric peptides. Note, de-novo sequencing cannot distinguish between leucine 21 and isoleucine and therefore, L represents either a leucine or an isoleucine residue in 22 case of the cis-spliced peptide motif. Sequence of peptides in each pool (A).PBMCs from the same patients and donors pre-18 stimulated with the pooled peptides as in Figure 6 were re-stimulated with single 19 peptides from the same pool after 12 days for 8 hours in the presence of BFA and 20 TNFα expression measured by ICS. DMSO and FEC served as negative or positive 21 control respectively (B). All peptides that stimulated CD8 + T cells as measured by 22
TNFα to a higher degree than DMSO in at least 1 patient plus some randomly picked 23 cis-spliced peptides were subjected to HLA-A2 stabilization assays on T2 cells as 24 described in M&M. None HLA-A2 binding peptides (B7) or the Melan-A modified 25 HLA-A2 epitope served as negative and positive control respectively.* denotes 1 immunogenic peptides. 2 3 4 Supplementary Tables: 1   Table 1 : All linear and cis-spliced peptides identified 2 
